help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 13, No. 3, 330-336, March 2008; doi:10.1634/theoncologist.2007-0159
© 2008 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisp...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ibrahim, T.
Right arrow Articles by Amadori, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ibrahim, T.
Right arrow Articles by Amadori, D.

Symptom Management and Supportive Care

Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study

Toni Ibrahima, Francesca Barbantib, Gianluca Giorgio-Marranob, Laura Mercatalia, Sonia Ronconia, Claudio Vicinib, Dino Amadoria

aOsteo-oncology Center and Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy; b Oral Surgery and Dentistry Department, Otorhinolaryngology Unit, Morgagni Pierantoni Hospital, Forlì, Italy

Key Words. Bisphosphonates • Bone metastasis • Jaw • Osteonecrosis

Correspondence: Correspondence: Dino Amadori, M.D., Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Maroncelli 40, 47014 Meldola, Italy. Telephone: 39-0543-739252; Fax: 39-0543-739249; e-mail: segronco{at}ausl.fo.it

Disclosure: No potential conflicts of interest were reported by the authors, planners, reviewers, or staff managers of this article.

Objective. Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bisphosphonates, which are also associated with avascular osteonecrosis of the jaw (ONJ). Our aim was to evaluate the correlation between bisphosphonates and ONJ.

Patients and Methods. Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i.v. bisphosphonates, eight (1.5%) developed ONJ.

Results. The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion.

Conclusions. Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2008 by AlphaMed Press.